Diagnostics specialist EKF benefited from a strong end to 2011 which prompted analysts to upgrade their earnings forecasts for the year and should give investors more confidence in its prospects for 2012.
IC TIP:
Buy
at
25.5p
Sales were boosted by a large order received in November from Mexico for EKF’s Hemo-Control haemoglobin testing device as well as continued strong sales of the Quo-Test desktop diagnostic kit. The Mexican deal more than made up for a delay in shipping HemoPoint H2 hemoglobin testing kits to US partner Alere, but shipments will begin in the current quarter and are expected to be a major driver during 2012.
